Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus
(RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children …

Respiratory syncytial virus (RSV) remains a significant cause of morbidity and mortality in
infants, immunocompromised patients and the elderly. Despite the high disease burden, an …

Respiratory Syncytial Virus (RSV) is a common virus that infects children and adults;
however, children younger than two years of age tend to develop more serious respiratory …

Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants,
young children, and older or immunocompromised adults. Although aerosolized ribavirin …

Introduction: Respiratory syncytial virus (RSV) is the major cause of lower respiratory tract
infections (LRTI) in infants, the elderly, and the immunocompromised. Although the …

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract
infections in infants and young children, accounting for more than 100,000 hospitalizations …

Respiratory syncytial virus (RSV) is an important respiratory pathogen in infants and children
worldwide. Although RSV typically causes mild upper respiratory infections, it frequently …

Respiratory syncytial virus (RSV) is a major virus pathogen of infants and young children, an
important cause of disease in adults and is responsible for a significant amount of excess …

Introduction: Respiratory syncytial virus (RSV) is an important pathogen in children and
adults; however, current treatment options are primarily supportive. Palivizumab, the only …

Respiratory syncytial virus (RSV) is a common and highly contagious pathogen that infects
nearly all children by the age of 2 years. It is responsible for significant morbidity and …